Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 5/20 | 0.34 |
| ▸ | PIM1 | P11309 | 5/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15868903 | 0.66 | ALK (0.32) | — | |
| SCHEMBL10126430 | 0.63 | POLB (0.44) | POLBMEN1CYP1A2KMT2A | |
| SCHEMBL31517757 | 0.61 | POLB (0.45) | POLBMEN1CYP1A2KMT2A | |
| SCHEMBL29868008 | 0.61 | POLB (0.42) | POLBMEN1KMT2A | |
| SCHEMBL8828513 | 0.60 | KMT2A (0.49) | POLBMEN1CYP1A2KMT2A | |
| SCHEMBL18704234 | 0.58 | PDPK1 (0.43) | POLBMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL27468195 | 0.58 | KMT2A (0.47) | POLBMEN1CYP1A2KMT2A | |
| SCHEMBL13780200 | 0.57 | KDM4E (0.40) | POLBMEN1KMT2A | |
| SCHEMBL13212446 | 0.57 | GAA (0.39) | — | |
| SCHEMBL14353515 | 0.56 | POLB (0.69) | POLBMEN1CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1970373-A1 | ALICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | CCR4, CCR1, HRH4 | NTRK1 4394/4885PIM1 1867/4885ACVR1 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.